Location of Repository

Development of evidence synthesis methods for health policy decision making - A chain of evidence approach

By Clare Louise Gillies

Abstract

This project comprises a critical exploration and development of methods for the synthesis of evidence, using a chain of evidence approach, from diverse, yet inter-related, sources. The methodologies were explored through the development of a comprehensive decision model to assess different health policies in respect to screening for type 2 diabetes mellitus (T2DM). Four strategies were compared which were, no screening (current policy), screening for T2DM alone allowing for early diagnosis and treatment of the condition, and two strategies whereby both impaired glucose tolerance (IGT) and T2DM were screened for, allowing for early treatment of T2DM and for either lifestyle or pharmacological interventions to be applied to those with IGT in an attempt to delay the onset of T2DM. The comprehensive decision model developed here was innovative when compared to current published models in a number of ways. Firstly the entire model was encompassed within a single flexible framework, which has a number of advantages, and secondly as much of the available data as was feasible to use, was incorporated into the model inputs. A number of methodological issues and techniques were explored during the development of the comprehensive decision model. These included mixed treatment comparison analyses, assessment of baseline risk on intervention effects and the use of individual patient data. A number of sensitivity analyses and model extensions were carried out to assess the parameters with most influence on model results, and to adapt the model to different screening scenarios. The results of the model provide evidence that a screening strategy for IGT and T2DM, followed by appropriate treatment and interventions appears to be a cost-effective screening strategy. Uncertainty still surrounds the cost-effectiveness of screening for T2DM alone and further research is required. Running decision models within a Bayesian, comprehensive decision modelling framework, allows for model flexibility and has advantages over more conventional modelling techniques

Publisher: University of Leicester
Year: 2007
OAI identifier: oai:lra.le.ac.uk:2381/7462

Suggested articles

Preview

Citations

  1. (UKPDS) GROUP (1998b) Tight blood pressure control and risk of macrovascular and microvascular complications
  2. (2003). A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer.
  3. (2002). A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence.
  4. (2002). A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.
  5. (2001). A computer simulated model for costeffectiveness analysis of mass screening for Type 2 diabetes mellitus.
  6. (1996). A likelihood approach to meta-analysis with random effects.
  7. (2004). A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68).
  8. (2007). A pharmacoeconomical model for choice of a treatment for pregnant women with gestational diabetes.
  9. (2007). A systematic review and economic evaluation of statins for the prevention of coronary events.
  10. (1999). A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance.
  11. (2000). ABC of arterial and venous vascular disease: Vascular complications of diabetes.
  12. (2002). Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial.
  13. (1988). An assessment of clinically useful measures of the consequences of treatment.
  14. (1990). An Introduction to a Bayesian method for meta-analysis: The confidence profile method.
  15. (2004). Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review.
  16. (1996). Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clinical Trials,
  17. (1997). Assessing uncertainty in cost-effectiveness analyses: Application to a complex decision model.
  18. (2007). Baseline charactersitics and risk of progression from prediabetes to type 2 diabetes in a multiethnic, population based screening.
  19. (2006). Bayesian analysis in Stata using WinBUGS.
  20. (2004). Bayesian approaches to clinical trials and health-care evaluation,
  21. (1999). Bayesian approaches to meta-analysis of ROC curves.
  22. (2003). Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
  23. (2001). Bayesian methods in meta-analysis and evidence synthesis.
  24. (1999). Bayesian Model Averaging - A Tutorial (with discussion).
  25. (1994). Bayesian theory,
  26. (1997). Bias in meta-analysis detected by a simple graphical test.
  27. (1973). Borderline diabetics and their response to tolbutamide.
  28. (2006). Bringing health economic modeling to the 21st century.
  29. (1998). Cholesterol and coronary heart disease: screening and treatment.
  30. (1998). Cholesterol reduction yields clinical benefit: impact of statin trials.
  31. (2007). Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routing healthcare setting: model based on the KORA Survey
  32. (2005). Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
  33. (2005). Cochrane Handbook for Systematic Reviews of
  34. (2005). Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
  35. (2004). Combination of direct and indirect evidence in mixed treatment comparisons.
  36. (2004). Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach.
  37. (1998). Confidence intervals for the number needed to treat.
  38. (1999). Consequences of the new diagnostic criteria for diabetes in older men and women: The DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe).
  39. (2007). Correction: Interpretation of random effects meta-analysis in decision models.
  40. (2004). Cost-effectiveness analysis of different screening procedures for Type 2 Diabetes. Diabetes Care,
  41. (1999). Cost-effectiveness of azithromycin for preventing Myobacterium avium complex infection in HIV-positive patients in the era of highly active antretroviral therapy.
  42. (2000). Cost-effectiveness of colonoscopy in screening for colorectal cancer.
  43. (1998). Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus.
  44. (2004). Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes.
  45. (2003). Costs of screening for pre-diabetes among U.S. adults.
  46. (1994). Costs, effects and costeffectiveness ratios alongside a clinical trial.
  47. (2002). Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
  48. (2002). Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
  49. (2001). Decision making in health and medicine: Integrating evidence and values,
  50. (2006). Decision modelling for health economic evaluation,
  51. (1998). Definition, diagnosis and classification of diabetes mellitus and it's complications. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation.
  52. (1999). Definition, diagnosis and classification of diabetes mellitus and its complications.
  53. (1994). Determining transition probabilities.
  54. (2004). Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP).
  55. (1980). Diabetes Mellitus,
  56. (1985). Diabetes Mellitus.
  57. (2005). Diabetes prevention: A review of current literature.
  58. (2000). Diabetes risk score: Towards earlier detection or type 2 diabetes in general practice.
  59. (2006). Diabetes: The pandemic and potential solutions. Disease control priorities in developing countries.
  60. (1999). Economic evaluation of alternative indicators for screening for diabetes mellitus.
  61. (2007). Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.
  62. (2004). Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
  63. (2004). Effect of exercise training in patients with impaired glucose tolerance. Zhongguo Linchuang Kangfu,
  64. (2004). Effect of jiangtang bushen recipe in intervention treatment of patients with impaired glucose tolerance.
  65. (2004). Effect of medicine and non-medicine intervention on the outcomes of patients with impaired glucose tolerance: 5-year follow-up. Zhongguo Linchuang Kangfu,
  66. (1999). Effect of metformin on patients with impaired glucose tolerance.
  67. (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care,
  68. (2004). Effects of life style intervention on early insulin secretion in the patients with impaired glucose tolerance. Zhongguo Linchuang Kangfu,
  69. (2005). Effects of nateglinide in impaired glucose tolerance subjects.
  70. (2000). Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
  71. (2003). Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.
  72. (2003). Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.
  73. (2005). Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomised controlled trials.
  74. (2005). Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes.
  75. (2005). Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty- when is there sufficient evidence? Value in Health,
  76. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making,
  77. (2007). Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods.
  78. (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III).
  79. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
  80. (1999). Fasting proinsulin concentrations predict the development of type 2 diabetes.
  81. (1995). Frailty models for survival data.
  82. (2007). General methods for monitoring convergence of iterative simulations.
  83. (1998). Global burden of diabetes, 1995-2025: prevalence numerical estimates, and projections.
  84. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care,
  85. (1999). Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.
  86. (2006). Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality of assessment.
  87. (2004). Guide to the methods of technology appraisal.
  88. (2007). HbA1c as a screening tool for detection of type 2 diabetes: a systematic review.
  89. (1994). Helping doctors to draw appropriate inferences from the analysis of medical studies.
  90. (2005). How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in
  91. (2007). Impaired fasting glucose and impaired glucose tolerance. Diabetes care,
  92. (2002). Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention.
  93. (2000). Implementation and performance issues in the Bayesian and likelihood fitting of multilevel models.
  94. (2002). Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance.
  95. (2005). Increased utilization of primary care 5 years before diagnosis of Type 2 diabetes.
  96. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
  97. (2004). Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
  98. INVESTIGATORS (2006a) Effect of ramipril on the incidence of diabetes.
  99. INVESTIGATORS (2006b) Effect of roglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
  100. (2005). Issues in evidence synthesis for comprehensive decision models: An illustration using impaired glucose tolerance. The International Society of Clinical Biostatistics,
  101. (2002). Issues on the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes.
  102. (2005). Japan Diabetes Prevention Program. Nippon Rinsho -
  103. (2006). Kamlesh Khunti. Development of Evidence Synthesis Methods for the Assessment of Health Policies Involving Screening and Intervention. The International Society of Clinical Biostatistics,
  104. (2007). Lifestyle changes and pharmacological interventions are both effective in protecting against type 2 diabetes mellitus but which approach is best? GP magazine.
  105. (2007). Lifestyle interventions are cost-effective in people with different levels of diabetes risk.
  106. (2006). Links Improving ecological inference using individual-level data.
  107. (2001). Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance.
  108. (2006). Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
  109. (2005). Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: A review.
  110. (2005). Longterm non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews,
  111. (1996). Markov Chain Monte Carlo convergence diagnostics: A comparative review.
  112. (1996). Markov Chain Monte Carlo in Practice,
  113. (1997). Markov Chain Monte Carlo. Stochastic Simulation for Bayesian Inference., Chapman and Hall.
  114. (2003). Measuring inconsistency in meta-analyses.
  115. (2000). Methods for Meta-Analysis in Medical Research,
  116. (2005). Methods for the economic evaluation of health care programmes,
  117. (1999). Methods in health service research: An introduction to Bayesian methods in health technology assessment.
  118. (2006). Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
  119. (1997). Modeling valuations for EuroQol health states.
  120. (1994). Modelling survival data in medical research,
  121. (2005). Need for differential discounting of costs and health effects in cost effectiveness analysis.
  122. (1998). No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise.
  123. (2004). Non-steroidal anti-inflammatory drugs and colorectal cancer prevention.
  124. (1992). Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis.
  125. (1994). Operating characteristics of a rank correlation test for publication bias.
  126. (2002). Optimal drug therapy of glucose intolerance is a guarantee of successful prevention of type 2 diabetes mellitus.
  127. (2003). Options for screening for colorectal cancer.
  128. (1999). Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke.
  129. (2007). Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance.
  130. (2007). Population screening for colorectal cancer: Faeces, endoscopes or xrays?
  131. (2004). Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study.
  132. (1991). Practical statistics for medical research, Chapman and Hall.
  133. (1997). Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies.
  134. (2002). Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women.
  135. (2004). Preventing Type II Diabetes Mellitus.
  136. (2003). Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial.
  137. (1994). Prevention of Diabetes Mellitus.
  138. (2006). Prevention of diabetes.
  139. (1991). Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study.
  140. (2005). Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.
  141. (2004). Prevention of Type 2 Diabetes in Subjects with Impaired Glucose Tolerance.
  142. (2004). Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting.
  143. (2005). Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
  144. (1999). Prevention of Type II diabetes in subjects with impaired glucose tolerance: The Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme.
  145. (2006). Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups.
  146. (1976). Primary, secondary and meta-analysis of research.
  147. (2003). Probabilistic sensitivity analysis for decision trees with multiple branches: Use of a dirichlet distribution in a bayesian framework.
  148. (1999). Problems with interval estimates of the incremental cost-effectiveness ratio.
  149. (2006). Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION study,
  150. (2002). Quantifying heterogeneity in a meta-analysis.
  151. (2001). Ramipril and the development of diabetes.
  152. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
  153. (2001). Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study.
  154. (1997). Report of the expert committee on the diagnosis and classification of diabetes mellitus.
  155. (2006). Screening for impaired glucose tolerance and intervening to delay type 2 diabetes mellitus: Is this an effective health policy? Cambridge Diabetes Seminar,
  156. (2004). Screening for Type 2 diabetes mellitus: A cost-effectiveness analysis.
  157. (2007). Screening for type 2 diabetes: literature review and economic modelling.
  158. (2007). Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria.
  159. (2006). Simultaneous comparison of multiple treatments: combining direct and indirect evidence.
  160. (2003). Six-year results from the Early Diabetes Intervention Trial.
  161. (2003). STAR: screening those at risk: study design and recruitment.
  162. (2001). Stata Statistical Software, College Station: Stata Corporation.
  163. (1993). Statistical Models in Epidemiology,
  164. (1991). Study design, progress and performance (UKPDS VIII).
  165. (2004). Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
  166. (1980). Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation.
  167. (2000). The ADDITION study: proposed trial of the cost-effectiveness of an intensive multi-factorial intervention on morbidity and mortality among people with Type 2 diabetes screen detected by screening.
  168. (1989). The confidence profile method: A Bayesian method for assessing health technologies.
  169. (2005). The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
  170. (1998). The cost-effectiveness of screening for Type 2 diabetes.
  171. (1989). The deadly quartet: upper body adiposity, glucose intolerance, hypertriglyceridaemia and hypertension.
  172. (2000). The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria
  173. (2003). The diabetes risk score: A practical tool to predict type 2 diabetes risk.
  174. (2003). The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity.
  175. (2006). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
  176. (2005). The interpretation of random-effects meta-analysis in decision models.
  177. (2003). The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging.
  178. (1997). The Stroke Prevention Policy Model: Linking evidence and clinical decisions.
  179. (1984). The Whitehall study: Ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death.
  180. (1996). Thioctacid T increases glucose utilization and reduces insulin resistance.
  181. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.
  182. (2002). Type 2 diabetes prevention: Education, or medication too?.
  183. (1999). Uncertainty of incremental costeffectiveness ratios. A comparison of Fieller and bootstrap confidence intervals.
  184. (1996). Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews.
  185. (2006). Unit costs of health and social
  186. (2007). Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis.
  187. (2000). Using the Framingham model to predict heart disease in the United Kingdom: retrospective study.
  188. (2006). Using value of information analysis to prioritise health research.
  189. (2006). What determines the cost-effectiveness of diabetes screening?
  190. (2001). Which colon cancer screening test? A comparison of cost-effectiveness and compliance.
  191. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.